No – Give PCV13 First, Not PPSV23
In a child with low pneumococcal antibody titers, the next step is to administer PCV13 (pneumococcal conjugate vaccine), NOT PPSV23 directly. PPSV23 should only be given at least 8 weeks after completing the PCV13 series, and only in children with specific high-risk conditions 1, 2.
Why PCV13 Must Come First
The sequence matters critically because:
- Conjugate vaccines (PCV13) generate immunologic memory and prime the immune system, while polysaccharide vaccines (PPSV23) do not 2
- Giving PPSV23 before or without PCV13 may cause hyporesponsiveness – meaning the immune system becomes less able to respond to subsequent pneumococcal vaccines, including PCV13 2
- PCV13 provides superior protection in children through T-cell dependent responses, reduction in nasopharyngeal carriage, and evidence of effectiveness against non-invasive disease like pneumonia and otitis media 2
The Correct Vaccination Algorithm
For PPSV23-Naïve Children (Ages 6-18 years) with High-Risk Conditions:
Step 1: Administer PCV13 first 1
Step 2: Wait at least 8 weeks 1, 2
Step 4: For highest-risk children (functional/anatomic asplenia, HIV, other immunocompromising conditions), give a second PPSV23 dose 5 years after the first 2
High-Risk Conditions That Warrant This Sequential Approach Include:
- Anatomic or functional asplenia (including sickle cell disease)
- HIV infection
- Immunocompromising conditions
- Cochlear implants
- CSF leaks
- Chronic renal failure
- Diabetes mellitus
- Other conditions listed in ACIP guidelines 1, 2
Critical Pitfalls to Avoid
Do not give PPSV23 first or alone in children. Research shows that PPSV23 administered without prior PCV priming provides minimal additional serotype protection and may actually impair future vaccine responses 3. One study demonstrated that PPV23 did not significantly increase protective antibody concentrations to non-PCV7 serotypes in children aged 2-16 years 3.
The concern about hyporesponsiveness is real. Studies in adults have documented that unconjugated polysaccharide antigens can induce lower antibody responses upon rechallenge with pneumococcal antigens 2. While the clinical significance remains uncertain, the theoretical risk is sufficient to mandate PCV13-first strategies 2.
For Healthy Children Without Risk Factors
- Healthy children aged 24-59 months need only one dose of PCV13 2
- PPSV23 is not recommended for healthy children without underlying medical conditions 2
- Routine use of PCV13 is not recommended for healthy children ≥5 years 2
If the Child Already Received PPSV23
If a child has already received PPSV23, they should still receive the recommended PCV13 doses, administered at least 8 weeks after the most recent PPSV23 dose 2. This applies even though it's not the ideal sequence.